<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01771653</url>
  </required_header>
  <id_info>
    <org_study_id>KOI-SIUSOM-12-002</org_study_id>
    <nct_id>NCT01771653</nct_id>
  </id_info>
  <brief_title>Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection</brief_title>
  <official_title>Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern Illinois University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southern Illinois University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational study is to compare two approved treatment regimen(s)
      containing boceprevir and telaprevir, as part of standard of care for the treatment of
      hepatitis C.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the study is to compare the effect of adding 2 oral hepatitis C virus (HCV)
      protease inhibitors, telaprevir versus boceprevir, as part of current standard treatment
      regimen with (pegylated-interferon-alpha + ribavirin) for HCV Genotype-1 infection. Data will
      be obtained from medical records of consenting patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Virologic Response</measure>
    <time_frame>up to 96 weeks post treatment</time_frame>
    <description>Sustained Virologic Response (SVR) rates will be compared between the two arms of treatment through measured HCV RNA levels after 24 weeks, 48 weeks and 96 weeks after completion of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>24, 48, and 96 weeks post treatment</time_frame>
    <description>Comparison of rates and severity of adverse events between the two study arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of baseline variables on treatment outcome</measure>
    <time_frame>24, 48, and 96 weeks post treatment</time_frame>
    <description>Analyze the effects of baseline variables on treatment outcome between the two groups- age, race, social economic status.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">37</enrollment>
  <condition>Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>Previously treated</arm_group_label>
    <description>Data from patients who were previously treated with Peg, interferon (IFN), alfa, and ribavirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Previously untreated</arm_group_label>
    <description>Records of patients who have never received anti-HCV treatment.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Population of adults aged 18-64 years, diagnosed with HCV genotype 1, with an HCV RNA
        &gt;100,000. They should have had a liver biopsy within 5 years before enrollment. Lab work to
        determine eligibility includes an absolute neutrophil count of at least 1200 per cubic
        millimeter, a platelet count of at least 90,000 per cubic millimeter and a hemoglobin level
        of at least 12 g per deciliter
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age - 18-64 years

          -  HCV genotype 1

          -  HCV RNA &gt;100,000

          -  Liver biopsy within 5 years before enrollment

          -  Absolute neutrophil count of at least 1200 per cubic millimeter

          -  Platelet count of at least 90,000 per cubic millimeter

          -  Hemoglobin level of at least 12 g per deciliter

          -  Signed informed consent and Health Insurance Portability and Accountability Act
             (HIPAA) forms

        Exclusion Criteria:

          -  HCV genotypes other than genotype 1

          -  Immunocompromised conditions including HIV, transplant or immunosuppressive drugs

          -  Decompensated liver disease or hepatocellular carcinoma

          -  Any other types of active cancer

          -  Active autoimmune disorders

          -  Major psychiatric disorders

          -  Active drug or alcohol use

          -  Pregnancy or lactation

          -  Patients with allergy to any of the drugs used in this study

          -  Drugs that may interact with boceprevir or telaprevir as listed in the package insert
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janak Koirala, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern Illinois University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern Illinois University School of Medicine</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pi.vrtx.com/files/uspi_telaprevir.pdf</url>
    <description>telaprevir prescribing information</description>
  </link>
  <reference>
    <citation>Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001 Jul 5;345(1):41-52. Review.</citation>
    <PMID>11439948</PMID>
  </reference>
  <reference>
    <citation>Di Bisceglie AM, Lyra AC, Schwartz M, Reddy RK, Martin P, Gores G, Lok AS, Hussain KB, Gish R, Van Thiel DH, Younossi Z, Tong M, Hassanein T, Balart L, Fleckenstein J, Flamm S, Blei A, Befeler AS; Liver Cancer Network. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol. 2003 Sep;98(9):2060-3.</citation>
    <PMID>14499788</PMID>
  </reference>
  <reference>
    <citation>Witthoeft T, Hueppe D, John C, Goelz J, Heyne R, Moeller B, Teuber G, Wollschlaeger S, Baumgarten A, Simon KG, Moog G, Dikopoulos N, Mauss S. Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: the PRACTICE study. J Viral Hepat. 2010 Jul;17(7):459-68. doi: 10.1111/j.1365-2893.2009.01255.x. Epub 2010 Feb 11.</citation>
    <PMID>20158603</PMID>
  </reference>
  <reference>
    <citation>O'Brien TR, Everhart JE, Morgan TR, Lok AS, Chung RT, Shao Y, Shiffman ML, Dotrang M, Sninsky JJ, Bonkovsky HL, Pfeiffer RM; HALT-C Trial Group. An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLoS One. 2011;6(7):e20904. doi: 10.1371/journal.pone.0020904. Epub 2011 Jul 8.</citation>
    <PMID>21760886</PMID>
  </reference>
  <reference>
    <citation>Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011 Mar 31;364(13):1195-206. doi: 10.1056/NEJMoa1010494.</citation>
    <PMID>21449783</PMID>
  </reference>
  <reference>
    <citation>Koirala J, Gandotra SD, Rao S, Sangwan G, Mushtaq A, Htwe TH, Adamski A, Blessman D, Khardori NM. Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy. J Viral Hepat. 2007 Nov;14(11):782-7.</citation>
    <PMID>17927614</PMID>
  </reference>
  <reference>
    <citation>Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R; HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011 Mar 31;364(13):1207-17. doi: 10.1056/NEJMoa1009482.</citation>
    <PMID>21449784</PMID>
  </reference>
  <reference>
    <citation>Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011 Jun 23;364(25):2405-16. doi: 10.1056/NEJMoa1012912.</citation>
    <PMID>21696307</PMID>
  </reference>
  <reference>
    <citation>Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, MÃ¼llhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M; REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011 Jun 23;364(25):2417-28. doi: 10.1056/NEJMoa1013086.</citation>
    <PMID>21696308</PMID>
  </reference>
  <reference>
    <citation>McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM; PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010 Apr 8;362(14):1292-303. doi: 10.1056/NEJMoa0908014. Erratum in: N Engl J Med. 2010 Apr 29;362(17):1647. Dosage error in article text.</citation>
    <PMID>20375406</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2013</study_first_submitted>
  <study_first_submitted_qc>January 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2013</study_first_posted>
  <last_update_submitted>January 15, 2016</last_update_submitted>
  <last_update_submitted_qc>January 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C infection</keyword>
  <keyword>Hepatitis C Virus</keyword>
  <keyword>HCV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

